CYP19A1 and osteoporosis: Notably, the incidence of osteoporosis at 102 per 1,000 person-years almost tripled the rate obtained in an Israeli study with a similar distribution of survivors receiving endocrine therapy.27 Routine BMD tests conducted before aromatase inhibitors initiation15 could have detected previously undiagnosed prevalent cases instead of true incident cases, driving a sharp increase in diagnoses in the first 6 months.